Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor

被引：0
|
作者：
Aldrich, Jeffrey
Hu, Thomas
Switchenko, Jeffrey
Coskun, Ahmet
Gokmen-Polar, Yesim
Badve, Sunil
Bhave, Manali
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-04-14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-04-14
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impressive Remission of metastatic PDL-1 positive triple negative Breast Carcinoma with Atezolizumab and nab-Paclitaxel
    Jahn, K.
    Baum, D.
    Langanke, D.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E44 - E44
  • [2] In Situ Modification of Macrophages for Targeting PDL-1 in Triple Negative Breast Cancer
    Siddiqui, Armaan
    Dhandapani, Hemavathi
    Rather, Aijaz
    Ingle, Arvind
    Sharma, Deepak
    Tayalia, Prakriti
    MOLECULAR THERAPY, 2024, 32 (04) : 368 - 369
  • [3] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Heeke, Arielle L.
    Tan, Antoinette R.
    CANCER AND METASTASIS REVIEWS, 2021, 40 (02) : 537 - 547
  • [4] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Arielle L. Heeke
    Antoinette R. Tan
    Cancer and Metastasis Reviews, 2021, 40 : 537 - 547
  • [5] Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review
    Tavares, Dione Fernandes
    Ribeiro, Victoria Chaves
    Vieira Andrade, Marco Antonio
    Cardoso-Junior, Laercio Moreira
    Gomes Teixeira, Thiago Rhangel
    Varrone, Gabriela Ramos
    Britto, Renata Lopes
    ONCOLOGY REVIEWS, 2021, 15 (02)
  • [6] Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Collier, Katharine
    Weber, Zachary T.
    Jammihal, Tejas R.
    Kao, Katrina Z.
    Richardson, Edward T., III
    Keenan, Tanya
    Cohen, Ofir
    Manos, Michael P.
    Brennick, Ryan C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Dillon, Deborah A.
    Attaya, Victoria
    O'Meara, Tess
    Lin, Nancy U.
    Van Allen, Eliezer M.
    Rodig, Scott
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Wu, Catherine J.
    Wagle, Nikhil
    Stover, Daniel G.
    Shukla, Sachet A.
    Tolaney, Sara M.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [7] Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response
    Wang, Ce
    Feng, Guoshuang
    Zhu, Jingjing
    Wei, Kecheng
    Huang, Chen
    Wu, Zhenyu
    Yu, Yongfu
    Qin, Guoyou
    FUTURE ONCOLOGY, 2022, 18 (09) : 1055 - 1066
  • [8] Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
    Simmons, Christine E.
    Brezden-Masley, Christine
    McCarthy, Joy
    McLeod, Deanna
    Joy, Anil Abraham
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
    Lee, Jin Sun
    Yost, Susan E.
    Yuan, Yuan
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [10] SMOKING HISTORY AND PD-1/PDL-1 PATHWAY BLOCKADE: PREDICTING RESPONSE TO TREATMENT IN METASTATIC CANCER
    Sullivan, C. M.
    Lu, J.
    Kucharczyk, J.
    Vesselinovitch, D.
    Khurana, N.
    Matrana, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 569 - 569
12345